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Scotland; monitoring of future vaccine impact
Kimberley Kavanagh1*, Katy Sinka2, Kate Cuschieri3, John Love2, Alison Potts2, Kevin GJ Pollock2, Heather Cubie5,
Martin Donaghy2 and Chris Robertson1,2,4Abstract
Background: Estimation of pre-immunisation prevalence of HPV and distribution of HPV types is fundamental to
understanding the subsequent impact of HPV vaccination. We describe the type specific prevalence of HPV in
females aged 20–21 in Scotland who attended or defaulted from cervical screening using three specimen types;
from attenders liquid based cytology and from defaulters urine or self-taken swabs.
Methods: Residual liquid based cytology samples (n = 2148), collected from women aged 20–21 attending for their
first smear were genotyped for HPV. A sample (n = 709) from women who had defaulted from screening was also
made available for HPV testing through the use of postal testing kits (either urine samples (n = 378) or self-taken
swabs (n = 331)). Estimates of prevalence weighted by deprivation, and for the postal testing kit, also by reminder
status and specimen type were calculated for each HPV type. The distribution of HPV types were compared
between specimen types and the occurrence of multiple high-risk infections examined. The influence of
demographic factors on high-risk HPV positivity and multiple infections was examined via logistic regression.
Results: The prevalence of any HPV in young women aged 20–21 was 32.2% for urine, 39.5% for self-taken swab,
and 49.4% for LBC specimens. Infection with vaccine specific types (HPV 16, 18) or those associated with
cross-protection (HPV 31, 33, 45, 51) was common. Individuals were more likely to test positive for high-risk HPV if
they resided in an area of high deprivation or in a rural area. The overall distribution of HPV types did not vary
between defaulters and attenders. Multiple infections occurred in 48.1% of high-risk HPV positive individuals.
Excluding vaccine types the most common pairing was HPV 56 and 66.
Conclusions: Understanding of the pre-immunisation prevalence of HPV in young women puts Scotland in a prime
position to assess the early effect of vaccination as the first highly vaccinated cohorts of individuals enter the
screening programme. Differences in results with different specimen types must be taken into account when
monitoring the impact of vaccination programmes.
Keywords: Human papilloma virus, Vaccination, Prevalence, Multiple infectionsBackground
The prevalence and circulating genotypes of human pap-
illomavirus (HPV) infection in different study popula-
tions has recently been reported [1-3]. The incentive for
such studies is a need for better understanding of HPV
infection, but additionally to provide information to en-
able the impact of key changes in prevention, detection
and management of HPV-related disease. Of particular* Correspondence: kim.kavanagh@strath.ac.uk
1Department of Mathematics and Statistics, University of Strathclyde,
Glasgow G1 1XH, UK
Full list of author information is available at the end of the article
© 2013 Kavanagh et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orimportance is the introduction of HPV vaccine and in-
creasing availability and use of HPV tests within cervical
screening programmes.
A better understanding of the natural history and epi-
demiology of HPV feeds into models of vaccine impact
and cost effectiveness to inform decision-making on
HPV immunisation and future changes to cervical
screening. Defining a baseline against which to monitor
the impact of vaccination provides a means to measure
the earliest expected change - which is a decrease in the
prevalence of vaccine-specific HPV.ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sociated pathology in target age groups means that few of
the studies on HPV prevalence are generalizable. Esti-
mates of HPV prevalence in the general population often
come from studies that consider samples from cervical
screening programmes due to ease of sampling and avail-
ability of a link to cytology/disease status [1,3]. These fre-
quently include women across a wide age range. Such
studies may however introduce a bias if the prevalence of
HPV in those who default from screening differs substan-
tially from those who attend. In Scotland, attendance at
cervical screening is high overall (71.2% in the previous
3.5 years in 2012–13) but is lower in those aged 20–24
(53.5%) [4].
For an estimate of Cervarix® vaccine impact it is import-
ant to ascertain the effect of the vaccination programme
on the whole population, with particular focus on the age
group where these changes will be observed first. In
Scotland, cervical screening currently begins at age 20,
therefore it is one of the few countries in the world able to
detect early impacts of the vaccine which was introduced
in September 2008. The vaccine was implemented as rou-
tine in-school vaccination of those aged 12–13 with a
catch-up campaign for all those aged 13–17 years old at
the time [5] and achieved sustained high uptake [6]. In
order to monitor the immunisation programme, a comple-
mentary, systematic national public health HPV surveil-
lance programme was implemented in Scotland.
This paper describes the methods used to establish
representative population-based estimates of HPV preva-
lence in unvaccinated women aged 20–21 in Scotland.
By using two sampling methods, we examined the preva-
lence of HPV in those who attended for cervical screen-
ing and in those who did not and the distribution of
HPV types detected. We aimed to improve the represen-
tativeness of the baseline HPV prevalence estimates and
compare patterns between those who default from and
those who attend for screening. In addition, we exam-
ined the effect of different specimen types upon esti-
mates of HPV prevalence. The occurrence of multiple
HPV types is examined with particular emphasis on co-
incidence of high-risk vaccine types (16 and 18) with
other high-risk types. Such estimates are fundamental to
understanding the impact of the HPV vaccination in the
general population, while validating the public health ap-
proach taken in Scotland.
Methods
Sampling and surveys
Scotland has a population of approximately 5.3 million [7]
and an organised cytology based cervical screening prog-
ramme. Screening age is currently 20 to 60 years and
women are first invited to attend after their 20th birthday.
Following this invitation, if they do not attend they aresent two reminder invitations at three monthly intervals
and are classified as “defaulters” if they have not attended
by three months following the second reminder. All
women in Scotland eligible for cervical screening are re-
corded in the Scottish Cervical Screening Call and Recall
System (SCCRS), a population-based information technol-
ogy system, which supports the programme and contains
pathology results, recall and management information.
Population attending for screening
In 2009, anonymised residual liquid based cytology
(LBC) samples from young women aged 20–21 years at-
tending their first screening appointment were collected
from all (11) NHS cytopathology laboratories in
Scotland, which have national coverage. To achieve the
desired sample size of 2,000 specimens, each laboratory
collected over a two month period, staggered throughout
the year, and selected samples from women born after
1st January 1988, with the number of samples collected
proportionate to the population which the laboratory
served.
Population defaulting from screening
Self-taken specimens were obtained using a postal test-
ing kit (PTK) for women who defaulted from attending
their first screening appointment in 2008. From an
anonymised data file of 15367 women, 5500 were ran-
domly selected across all Health Board administration
areas ensuring a geographically representative sample.
Half of the randomly selected women were sent a urine
test kit and half a self-taken vaginal swab kit. Details of
the methodology are reported elsewhere [8].
Data and linkage
All LBC, swab and urine specimens were labelled with a
study identification number. The study ID was separately
linked to SCCRS data using the unique Community Health
Index identifier. Geographical datazone, derived from post-
code of residence, was attributed to each record. HPV re-
sults were matched to each record and all personal
identifiable information was then removed from the dataset
prior to statistical analysis. The Scottish Index of Multiple
deprivation (SIMD) quintiles (1: Most deprived; 5: Least de-
prived) and urban–rural six-fold classification were ex-
tracted from the Scottish Neighbourhood Statistics (http://
www.sns.gov.uk) and linked to the dataset via datazone. The
percentage of non-white residents in each datazone (“white”
defined as White Scottish, White Irish, White Other British
or Other White according to the ethnicity question in the
2001 census) was obtained from http://www.scrol.gov.
uk/scrol/warehouse/NewWards_ER_OA.jsp for the cen-
sus output areas and the aggregated up to data zones.
As high concentrations of non-white individuals are
Kavanagh et al. BMC Infectious Diseases 2013, 13:519 Page 3 of 8
http://www.biomedcentral.com/1471-2334/13/519clustered within a small number of datazones, this vari-
able was categorised into quintiles.
As a large proportion of individuals reside in urban clas-
ses 1 (large urban) or 2 (other urban), reflecting the popula-
tion distribution in Scotland, the urban–rural classification
was recoded so that categories 3 (accessible small towns)
and 4 (remote small towns) are combined to form a small
town class and 5 (accessible rural) and 6 (remote rural) a
rural class giving a suitable number of specimens in each
level.
HPV testing
All LBC samples were collected in ThinPrep media
whereas swab samples were collected within M4RT media
(Remel Products, Thermo Scientific, Lenexa, KS, USA).
Urine was collected in 20 ml universals without any stabil-
isation or preservative buffer. A 5 ml aliquot of urine sam-
ples was centrifuged and the pellet washed twice with
Phosphate Buffered Saline (PBS) before reconstitution in
1 ml of PBS prior to extraction. Self-taken swabs and re-
sidual LBC samples were vortexed and a 1 ml aliquot used
for extraction. Automated extraction for both sample
types was performed used the MDX media Kit (Qiagen
Ltd, Manchester, UK). As this automated platform incor-
porates batch extraction in a 12 × 8 grid format 10% of all
samples constituted HPV negative internal quality control
material, the grid reference of which varied across batches
as a contamination check. In addition previously tested
positive control material was also included within each
batch. HPV amplification and genotyping was performed
using biotinylated GP5 + 6+ primers, prior to downstream
genotyping using the Digene HPV Genotyping RH test
(Qiagen). This assay is capable of detecting 18 high-risk or
putatively high-risk types according to current IARC clas-
sification [9], specifically the 12 types in Group 1 with
“carcinogenic” status: HPV 16,18,31,33,35,39,45,51,52,56,
58,59, the single type in Group 2A with “probably carcino-
genic” status: HPV 68 and 6 types from Group 2B with
“possibly carcinogenic” status: HPV 26,53,66,73,82. Other
HPV types, including types 6 and 11 are not differentiated
but identified as “HPV other”.
Four grouped definitions were created; positive for any
HPV type, positive for the vaccine types 16 and 18, posi-
tive for the HPV types where some vaccine cross-
protection has been demonstrated – HPV 31, 33, 45 and
51 [10] and finally, positive for any high-risk type
(Group 1 and Group 2A [9]). In addition, individuals
with multiple infections (infected with more than one
HPV type) were identified.
Statistical analysis
The sample size was determined by the design of the
long-term surveillance system, where the primary aim is
to detect changes in HPV positivity over time. 2000 LBCsamples were collected from unvaccinated women in the
baseline year. The target sample size in the postal testing
kit study was 1000 in order to give a 90% power to de-
tect differences in HPV positivity of ± 6% points between
screening defaulters and attenders. The actual sample
achieved was 709, from a 13.2% response rate to the
study, see [8] for more details.
To obtain representative estimates of HPV prevalence
from the PTK sample, weights were calculated by raking
which matches marginal distributions of a survey sample
to known population margins [11]. Observations were
weighted according to the distribution of SIMD, speci-
men type (urine or swab) and reminder status in the
PTK sample. The LBC samples obtained were weighted
proportionately to the distribution of SIMD in the co-
hort of young women aged 20–21 years available for
sampling – the SCCRS extract.
The discrepancy in the distribution of HPV types de-
tected by each of the specimen types was assessed using a
simulation test using 1000 simulations as described in
Cuschieri et al. [12]. The distribution of HPV types for
each specimen type was compared to the overall distribu-
tion of HPV types from all specimens. The simulated p-
value was calculated from the proportion of simulations
with a discrepancy greater that that observed in the data.
In such a way it can be established if different patterns in
HPV type positivity are found between the specimen types
and therefore between screening defaulters and attenders.
The odds of HPV infection given urban/rural classifica-
tion, the proportion of non-white residents and SIMD of
the datazone of residence were estimated in both a uni-
variable and multivariable model using survey weighted
logistic regression adjusting for the specimen type – LBC,
self-taken swab or urine – and using a linear trend test for
the ordered variables. Interactions between each of SIMD,
the proportion of non-white residents and urban/rural
classification with specimen type were examined.
All analysis was carried out using the statistical software,
R version 2.12.2 [13] with use of the survey library [14].
Ethics
Self-taken sample collection was approved by West of
Glasgow Ethics Committee [09/S0703/13]. National sur-
veillance has been approved through the NHS National
Clinical Governance committees and Caldicott Guardians
at individual NHS Boards. Data linkage of information
was approved by the NHS National Services Scotland
(NSS) CHI advisory group.
Results
Demographics
Characteristics of the cervical screening and self-sampling
groups are shown in Table 1. HPV test results were avail-
able for 2148 residual LBCs and 709 self-taken samples
Table 1 Comparison those attending their first screening
appointment, defaulters who provided a self-taken
sample, and the SCCRS cohort
Attenders Defaulters Cohort
Liquid
based
cytology
samples
Self-taken
samples
Extract of
registered
women
from
SCCRS
n % n % n %
SIMD
1: Most deprived 470 22.8 145 20.5 9204 22.3
2 481 23.3 125 17.6 8689 21.1
3 400 19.4 129 18.2 7515 18.2
4 333 16.1 147 20.7 7262 17.6
5: Least deprived 378 18.3 163 23.0 8545 20.7
Proportion of non-white residents
in datazone
Q1 [0.0%-0.4%) 458 22.2 151 21.3
Q2 [0.4%-1.0%) 450 21.8 137 19.3
Q3 [1.0%-2.0%) 431 20.9 135 19.0
Q4 [2.0%-5.3%) 398 19.3 136 19.2
Q5 [5.3%-65.6%) 325 15.8 150 21.2
Datazone urban/rural
1: large urban 991 48.1 339 47.8
2: other urban 626 30.4 196 27.6
3-4: accessible/remote small
towns
204 9.9 83 11.7
5-6: accessible/remote rural 241 11.7 91 12.8
SIMD is the Scottish Index of Multiple Deprivation. The proportion of
non-white residents in each area is derived from 2001 census data. SCCRS is
the Scottish Cervical Call/Recall System which all women eligible for screening
in Scotland are recorded on.
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ples. SIMD could not be linked to 86 of the LBC samples
which were subsequently excluded from the analysis.
Weighted prevalence estimates and type distribution
The prevalence of any HPV was 32.2% for the urine, 39.5%
for the self–taken swab, and 49.4% for the LBC samples
(Table 2). Type 16 and/or 18 was detected in 10% of the
urines, compared with 16.6% of the self-taken swabs and
23% of the LBCs. For any high-risk HPV, the respective
prevalence estimates were 19.1%, 29.1% and 41.2%, for
high-risk types excluding 16 and 18, 13.2%, 20.6% and
32.3% and for high-risk types excluding the cross protection
types, 8%, 11.2% and 21.5%. The unadjusted odds of detec-
tion of high-risk HPV positivity was reduced for the self–
taken swabs compared to the LBC samples (OR = 0.59 (95%
CI: 0.45, 0.76), p = 0.001) and similarly for the urine samples
(OR = 0.34 (95% CI: 0.26, 0.44), p < 0.0001) (Table 3).Type specific analyses (Figure 1) by specimen type
demonstrate that type 16 is the most predominant HPV
type with LBC samples having the highest prevalence
(18.1% (95% CI: 16.4, 19.8%)). Generally the prevalence
for each HPV type is highest for LBC samples, followed
by self-taken swabs and then urine.
Comparison of the distributional spread of HPV types,
excluding the “HPV other” category, showed that the
aggregated PTK sample (urines and swabs together) did
not have a significantly different distribution compared
to the LBC samples (p = 0.470) indicating little difference
in HPV types between those who defaulted and those
who attended screening. Within the PTK sample, urine
and self-taken swabs were found to have a different dis-
tribution of types (p = 0.032) with higher detection of
HPV types 16, 56, 18, 51, and 45 in the self-taken swabs
compared to urine.Which factors influence high-risk HPV positivity?
Adjusting for the effect of specimen type, urban/rural
classification, SIMD and proportion of non-white resi-
dents were all found individually to have a statistically
significant linear trend effect on positivity (p-value for
urban/rural, p = 0.0029, proportion of non-white resi-
dents quintile, p < 0.0001, SIMD p = 0.002). No signifi-
cant interactions were found (SIMD*specimen type, p =
0.119, proportion of non-white residents*specimen type,
p = 0.08, urban/rural*specimen type, p = 0.858). In the
multivariable model, the linear effect of quintile of non-
white residents became statistically non-significant (p =
0.497) and was removed from the model.
The reduced model showed a linear effect of SIMD
(p = 0.00071) and of urban/rural residence (p = 0.0014)
and a difference between the specimen types (p <
0.0001). The adjusted odds ratios indicate that individ-
uals in SIMD4 and SIMD5 (least deprived) had lower
odds of high-risk HPV positivity than those in SIMD1
(most deprived) (Table 3). The odds of any high-risk
HPV infection for individuals in rural areas (classes 5–6)
were 1.68 times more than those in the large urban areas
(class 1). There was an increase in the odds of high-risk
HPV positivity for those living in other urban areas
(class 2) in comparison to large urban areas (adjusted
OR = 1.41(95% CI: 1.16, 1.66)). There is a strong associ-
ation between deprivation and urban rural status. Of
those individuals from large urban areas nearly 30% were
highly deprived (SIMD1) compared to 22% overall while
among those who live in remote rural areas there are
few in SIMD 1 or 5. This association had no impact on
the ORs of being high-risk HPV positive implying that
the SIMD gradient associated with HPV positivity is the
same in large urban areas as in other areas (interaction
test p = 0.477).
Table 2 Weighted prevalence of HPV and corresponding 95% confidence interval (CI) stratified by sample type
Urine Self-taken swab LBC
HPV type Prevalence 95% CI Prevalence 95% CI Prevalence 95% CI
Any HPV 32.2% (27.4, 37.0)% 39.5% (34.2, 44.9)% 49.4% (47.2, 51.5)%
HPV 16 or 18 10.0% (6.8, 13.1)% 16.6% (12.5, 20.7)% 23.0% (21.2, 24.8)%
HPV 31 or 33 or 45 or 51 9.3% (6.4, 12.3)% 13.5% (9.7, 17.3)% 19.1% (17.4, 20.8)%
Any high-risk HPV 19.1% (15.0, 23.1)% 29.1% (24.1, 34.1)% 41.2% (39.1, 43.4)%
High-risk excluding HPV 16 or 18 13.2% (9.8, 16.7)% 20.6% (16.2, 25.0)% 32.3% (30.2, 34.3)%
High-risk excluding HPV 16, 18, 31, 33, 45 or 51 8.0% (5.2, 10.8)% 11.2% (7.7, 14.7)% 21.5% (19.7, 23.2)%
PTK samples were weighted by SIMD, specimen type and reminder status. LBC samples were weighted by SIMD.
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Overall, 1271 individuals tested positive for any HPV
and 1021 for a high-risk HPV type. Of these 1021, 491
(48.1%) were infected with more than one high-risk
type, 17.7% of the total samples (n = 2771). Of those in-
fected with more than one high-risk HPV type, 58.4%
were infected with two types, 25.6% with three, 9.9%
with four, 4.3% with five and 1.8% with more than five.
The maximum number found in an individual was 8
high-risk HPV types.
HPV types most frequently found with the vaccine
specific types are summarised in Figure 2. The vaccine
specific pairing of types 16 and 18 occurred in 10.8% ofTable 3 Unadjusted and adjusted odds of infection with any
urban/rural classification
Unadjusted OR
Specimen type
LBC 1
Self-taken swab 0.59
Urine 0.34
SIMD
1: Most deprived 1
2 0.78
3 0.96
4 0.78
5 Least deprived 0.64
Urban rural classification
1: Large urban 1
2: Other urban 1.38
3-4: accessible/remote small towns 1.19
5-6: accessible/remote rural 1.60
Proportion of non-white residents in datazone
Q1 [0.0%-0.4%) 1
Q2 [0.4%-1.0%) 0.89
Q3 [1.0%-2.0%) 0.84
Q4 [2.0%-5.3%) 0.72
Q5 [5.3%-65.6%) 0.56those with multiple high-risk types. The most common
pairings with type 16, excluding type 18, were high-risk
HPV types 31, 56, 33 and 59. Types 31, 56 and 59 were
also the most common with type 18. Limiting the ana-
lysis to the non-vaccine types, the most common
pairing was types 56 and 66 (5.4% of those with multiple
types).
Amongst those positive for any high-risk HPV no sig-
nificant association was found between SIMD quintile
(p = 0.76), urban/rural status (p = 0.46) or ethnicity
quintile (p = 0.62) and the odds of having a multiple
high-risk HPV infection compared to a single high-risk
HPV. Differences were found in the odds of detectinghigh-risk HPV type for each specimen type, SIMD and
95% CI Adjusted OR 95% CI
- 1 -
(0.45, 0.76) 0.58 (0..45, 0.75)
(0.26, 0.44) 0.33 (0.25,0.44)
1
(0.62, 0.99) 0.73 (0.57, 0.93)
(0.75, 1.22) 0.87 (0.67, 1.12)
(0.60, 1.01) 0.69 (0.53, 0.91)
(0.49, 0.82) 0.62 (0.48, 0.80)
- 1 -
(1.15, 1.67) 1.41 (1.16, 1.71)
(0.90, 1.57) 1.25 (0.94, 1.66)
(1.24, 2.07) 1.68 (1.28, 2.20)
-
(0.70, 1.14)
(0.66, 1.08)
(0.56, 0.92)
(0.43, 0.73)
Figure 1 Weighted estimates of HPV prevalence stratified by sample type.
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types (p = 0.016) with fewer multiple infections detected
in self-taken samples in line with the reduced sensitivity
of these collection methods (Self taken swab OR = 0.61
(95% CI: 0.4, 0.96); Urine OR = 0.60 (95% CI:0.37, 0.98)).Figure 2 All high-risk HPV types occurring with HPV 16 (top panel, ex
those individuals with multiple high-risk HPV infections (n = 491).Discussion
It is a challenge to measure the prevalence of HPV since,
unlike many other infections, there is comparatively lit-
tle diagnostic type specific HPV testing which would
allow surveillance through existing data sets such ascluding HPV18) and HPV 18 (bottom panel, excluding HPV16) in
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ies are restricted to populations that attend for cervical
screening, those under investigation for cervical abnor-
malities detected or those accessing sexual health services
[15,16]. In this study of unvaccinated 20 and 21 year olds
in Scotland eligible for their first cervical screen, we have
obtained samples from both those attending screening
and defaulters, albeit the latter limited by a low response
rate to the PTK −13.2% [8], in order to estimate pre-
immunisation HPV prevalence in this cross-section of the
population.
Our original aim was to compare HPV positivity among
attenders for screening and defaulters but this comparison
is confounded with specimen type. The difference in
prevalence of 39.5% from the self-taken swab and 49.4%
from the nurse-taken LBC swab suggests that those who
do not attend for screening have a lower prevalence. This
is unlikely to be the case. As this study shows a consistent
gradient of increasing HPV positivity with increasing
SIMD deprivation levels and the screening defaulters have
a greater preponderance of SIMD1 (deprived) individuals
compared to those who attend for screening [8] we would
have anticipated greater HPV positivity among the de-
faulters. We therefore conclude that the differences are
likely due to the different specimen types and the baseline
HPV patterns within the defaulter population is likely to
be similar to the attenders - consequently the on-going as-
sessment of the impact of HPV vaccination in Scotland
will be based on LBC samples.
HPV infection was common in this population of young
women and multiple infections were detected in approxi-
mately half of all HPV positive samples. Baseline pre-
immunisation levels of the vaccine specific types were
high, with HPV 16 the more common than HPV 18. The
aggregate occurrence of non-vaccine types, in particular
those deemed to be high-risk, is more prevalent than the
vaccine specific types and our results are comparable to
those of other recent UK based studies [15,17].
Individual risk factors associated with HPV infection
status, such as sexual activity and ethnic minority back-
ground [17], were not available. Linkage allowed assign-
ment to each individual of SIMD, urban/rural designation
and proportion of non-white residents. These should
not be interpreted as individual attributes in this study.
In a fully adjusted model, significant association with
high-risk HPV positivity was found with increasing
deprivation and rural classification. Although there has
been some indication that individuals in rural areas may
have higher levels of risky sexual behaviour [18,19] this
is not well evidenced. However, this result is in accord-
ance with the findings from the school based prevalence
study carried out in Scotland which showed increasing
HPV positivity with increasing levels of deprivation and
in rural schools [20].There was no overall difference in the distribution of
HPV types between the aggregate PTK sample and the
LBC samples, implying that HPV patterns are similar in
both populations. In terms of prevalence estimates, urine
and self-taken swabs are not comparable to LBC samples
nor to each other but if used consistently could allow
trends to be monitored for surveillance purposes espe-
cially in those defaulting from screening [21].
Multiple high-risk HPV infections were common, with
around half of those infected having more than one type
detected. Quantifying and defining the extent of multiple
HPV infection is important as it may limit or enhance the
effectiveness of the immunisation programme. With re-
gard to the former, any increase in the prevalence of non-
vaccine high-risk genotypes due to type replacement
rather than unmasking could erode the programme’s cost-
effectiveness. On the other hand, cross protection of the
vaccine may somewhat mitigate against type replacement,
particularly against 31, 33 & 45. There is some evidence
suggesting that Cervarix® may confer relatively high levels
of cross-protection [22].
Sexual behaviour has been shown to influence the risk
of having multiple HPV infections and overall there are
differences between younger and older women in factors
that influence high-risk HPV positivity [23]. There is a
slight age gap between the two populations of young
women sampled (LBC and PTK). The LBC data were de-
rived from young women aged 20 and 21 in 2009 (ap-
proximate 50:50 split between the ages) whilst the PTK
were sent to women reaching 21 in 2008. There may
have been a secular increase in overall HPV prevalence
in the intervening time period. However, any effect that
this may have had is likely to be minimal given that
HPV infections can persist and given that we are meas-
uring prevalence rather than incidence.
Conclusions
Our study estimated the prevalence of HPV in unvaccin-
ated young women living in Scotland. This study was es-
sential in order to determine the baseline burden of HPV
infection before vaccination. Specimens were tested using
the same HPV assay at the same testing laboratory ensur-
ing consistency of results. Although the varying sensitivity
of the different specimen types in detecting HPV does not
allow direct comparison between the prevalence of HPV
in those attending screening and those defaulting, the
similarity in the type specific HPV prevalence distributions
and the consistent differences in the prevalence estimates
obtained from the three sample types suggest that the in-
fection pattern between defaulters and attenders is un-
likely to be substantially different.
Due to the low uptake of defaulters to the PTK [8] the
effectiveness of this tool for surveillance of changes in HPV
prevalence post vaccination is limited and is therefore
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able uptake of HPV vaccination achieved in young women
in Scotland [6], limiting surveillance to testing samples
from those attending screening is likely to estimate accur-
ately the effect of the vaccination on HPV prevalence in
young women overall.
We are now in a prime position to ascertain the early
effects of the HPV vaccine on young women who were
part of the initial vaccination campaign and who were
called for cervical screening from 2010. Having a sys-
tematic surveillance programme which has included the
characterisation of a pre-vaccine baseline will allow us to
robustly determine these effects.
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